A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result

We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikushima, Wataru, Sakurada, Yoichi, Fukuda, Yoshiko, Matsubara, Mio, Kotoda, Yumi, Sugiyama, Atsushi, Kashiwagi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141467/
https://www.ncbi.nlm.nih.gov/pubmed/37111318
http://dx.doi.org/10.3390/ph16040562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141467/
https://www.ncbi.nlm.nih.gov/pubmed/37111318
http://dx.doi.org/10.3390/ph16040562

Ejemplares similares